Pharmacokinetics, safety, and efficacy of APF530 (extended-release granisetron) in patients receiving moderately or highly emetogenic chemotherapy: results of two Phase II trials

BACKGROUND: Despite advances with new therapies, a significant proportion of patients (>30%) suffer delayed-onset chemotherapy-induced nausea and vomiting (CINV) despite use of antiemetics. APF530 is a sustained-release subcutaneous (SC) formulation of granisetron for preventing CINV. APF530 phar...

Descripción completa

Detalles Bibliográficos
Autores principales: Gabrail, Nashat, Yanagihara, Ronald, Spaczyński, Marek, Cooper, William, O’Boyle, Erin, Smith, Carrie, Boccia, Ralph
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4370683/
https://www.ncbi.nlm.nih.gov/pubmed/25834466
http://dx.doi.org/10.2147/CMAR.S72626

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4370683/
https://www.ncbi.nlm.nih.gov/pubmed/25834466
http://dx.doi.org/10.2147/CMAR.S72626

Ejemplares similares